Research programme: HIV protease inhibitors - Roche
Latest Information Update: 09 Nov 2006
At a glance
- Originator Roche
- Class Small molecules
- Mechanism of Action HIV protease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 09 Nov 2006 Discontinued - Preclinical for HIV infections treatment in United Kingdom (unspecified route)
- 06 May 2001 New profile
- 06 May 2001 Preclinical development for HIV infections treatment in United Kingdom (Unknown route)